Patients with a high USP7 expression were more prone to chemoresistance, and USP7 inhibition (P22077) acts in synergy with cytarabine to kill acute myeloid leukemia cell lines with high USP7 levels, indicating that USP7 is both a marker of chemoresistance and a potential therapeutic target in enhancing chemosensitivity (Cartel et al., 2021). The gene discussed is USP7; the disease is acute myeloid leukemia.